Biofrontera AG banner

Biofrontera AG
LSE:0DOL

Watchlist Manager
Biofrontera AG Logo
Biofrontera AG
LSE:0DOL
Watchlist
Price: 1.15 EUR -51.89% Market Closed
Market Cap: €518.4k

Wall St Price Targets

0DOL Price Targets Summary
Biofrontera AG

There are no price targets for 0DOL.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Biofrontera AG Competitors:
Price Targets
SUPN
Supernus Pharmaceuticals Inc
45% Upside
PTCT
PTC Therapeutics Inc
43% Upside

Revenue
Forecast

25% / Year
Past Growth
32% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
25% / Year
Past Growth
32% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 1 year, the compound annual growth rate for Revenue has been 25%. The projected CAGR for the next 2 years is 32%.

Gross Profit
Forecast

24% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
24% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Biofrontera AG

Operating Income
Forecast

239% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
239% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Operating Income Forecast
is not available for Biofrontera AG

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Biofrontera AG

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Biofrontera AG
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0DOL's stock price target?
Not Available

0DOL does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Biofrontera AG?
Projected CAGR
32%

Over the last 1 year, the compound annual growth rate for Revenue has been 25%. The projected CAGR for the next 2 years is 32%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett